Backgrounds/Aims: Pancreatic leak and fistula formation following pancreatic resection is a dreaded complication associated with significant morbidity and mortality. The perioperative use of inotropes has been implicated in anastomotic dehiscence in other types of gastrointestinal surgery but their impact in pancreatic surgery remains unclear and a potentially modifiable risk factor for pancreatic leak. This study aims to assess the impact of perioperative inotrope infusion on the incidence of pancreatic leak following pancreaticoduodenectomy. Methods: Retrospective data analysis of all patients undergoing pancreaticoduodenectomy at a tertiary HPB institute. Multivariate analysis and regression models assessed the impact of inotrope use against other known risk factors such as pancreatic duct size and gland texture. Pancreatic fistulae were graded as per ISGPF as Grade A (biochemical leak), Grade B and Grade C fistula. Results: One-hundred and twenty-three (123) patients were included. A total of 52 patients (42%) developed a leak (29 grade A, 15 grade B, and 8 Grade C). In the fistula group, 28 patients (55%) received perioperative inotropes compared to 26 (35%) in the no fistula group. On univariate analysis, patients receiving inotropes (p=0.04) and patients with a soft pancreatic texture (p=0.003) had a statistically higher incidence of developing a pancreatic fistula of any grade. On multivariate analysis, only inotrope use was associated with an increased risk of developing a pancreatic fistula of any grade (OR 2.46, p=0.026), independent of pancreatic texture and pancreatic duct size. Conclusions: Perioperative inotrope use is associated with an increase incidence of pancreatic leak following pancreaticoduodenectomy and should therefore be used judiciously. 
INTRODUCTION
The mortality following pancreatic resection has declined yet morbidity remains high. 1, 2 Postoperative pancreatic fistula is a significant and dreaded complication following pancreatic resection with a reported incidence of 5%-29%. 3 Pancreatic fistula can result in sepsis, haemorrhage, prolonged hospital stay and death. Research focussing on modifiable risk factors remains of great interest to pancreatic surgeons striving to improve patient outcomes and identify high risk candidates. A soft pancreatic texture and small pancreatic duct have been consistently proven to be independent, albeit non-modifiable, risk factors for post-operative pancreatic leaks. [3] [4] [5] Any factor which affects oxygen delivery to the peri-anastomotic microcirculation such as hypotension, anaemia, intraoperative blood transfusion and excessive crystalloid therapy have also been implicated in anastomotic dehiscence; primarily studied in colorectal surgery. With the widening use of Goal-Directed Fluid Therapy (GDFT) and Enhanced Recovery pathways (ERAS) for major gastrointestinal surgery the utilisation of perioperative inotropic support is common-place and is now written into anaesthetic ERAS algorithms for treating hypotension. 6 Surgical concerns regarding the deleterious effect of inotropes on anastomotic healing are, however, based on a paucity of published evidence and continue to be debated. Theoretical vasopressor-induced splanchnic vasoconstriction can lead to shunting of microcirculation and local tissue hypoxia 7 yet experimental animal models have failed to show any sig- The aim of this study was to investigate whether perioperative inotrope infusion for major pancreatic surgery would independently impact on the incidence of pancreatic fistula formation. 
MATERIALS AND METHODS

RESULTS
A total of 123 patients were included in the study with a male to female ratio of 63:62. The median age was 67
(range 31-82) and median length of stay was 17 days The demographics of the two groups were similar. The impact of inotropes on developing clinically sig-nificant fistulas (only grade B and C) however, remains inconclusive as the low incidence of clinically significant fistulas in this study (23 fistulas) may lack the power to detect any statistically significant difference. This low incidence may also explain why no increase risk was detected in patients with a small caliber pancreatic duct; an independent risk factor shown in other studies. 5, 15, 16 Other weaknesses of this study include the bias inherently seen with retrospective data collection. In addition, two different anastomotic techniques were used by four different surgeons and was not factored into the analysis. However, previous studies have failed to show superiority of one technique over another. 17 Our findings support that of a previous study of 223 patients admitted to the intensive care unit following any gastrointestinal (GI) surgery. 10 They demonstrated a 3-fold increase in anastomotic leaks in all GI anastomoses when patients were treated with inotropes. The rates were higher when multiple agents were used for prolonged periods.
The leak group, however, had a small sample size (just 26 patients). Furthermore, the leak group contained various types of GI anastomosis including ileocolic anastomoses. This cohort heterogeneity is likely to limit any conclusions drawn from this study but did call for evidence-based guidelines for postoperative use of inotropes.
Another study of 140 major GI anastomotic leaks (40.9% of which were pancreatic resections) showed that as well as hypoalbuminaemia (＜35 g/L), anaemia (＜8 g/L), and need for blood transfusion, the use of intraoperative inotropes was independently associated with a four-fold increase risk of anastomotic leak (OR 4.11 95% CI 1.21-2.65, p=0.03). 9 Although this retrospective study has the largest series of leaks to date, the group remains heterogeneous in terms of type of surgery and pathology. The type or duration of inotropes used was also not reported and pancreatic leaks were not analysed in isolation.
Improvements in mortality, length of hospital stay and complications seen with goal-directed fluid therapy and ERAS pathways means the utilisation of vasopressors to optimise perioperative haemodynamic parameters is likely to remain a key adjunct in pancreatic and GI surgery. 18, 19 To date, the majority of published clinical data investigat- Larger studies are required before clear guidelines can be developed but current evidence would suggests inotropes should be used judiciously in the perioperative period after pancreatic resection.
